Discussion about this post

User's avatar
Jay See's avatar

And a relentlessly over-credulous AP to breathlessly "report" such garbage

Expand full comment
David Brown's avatar

There is a sense in which swapping saturated fatty acids for linoleic acid will consistently improve insulin sensitivity and reduce risk of cancer and heart attack. Norwegian animal scientists came up with the explanation back in 2010. "Because arachidonic acid (AA) competes with EPA and DHA as well as with LA, ALA and oleic acid for incorporation in membrane lipids at the same positions, all these fatty acids are important for controlling the AA concentration in membrane lipids, which in turn determines how much AA can be liberated and become available for prostaglandin biosynthesis following phospholipase activation. Thus, the best strategy for dampening prostanoid overproduction in disease situations would be to reduce the intake of AA, or reduce the intake of AA at the same time as the total intake of competing fatty acids (including oleic acid) is enhanced, rather than enhancing intakes of EPA and DHA only. Enhancement of membrane concentrations of EPA and DHA will not be as efficient as a similar decrease in the AA concentration for avoiding prostanoid overproduction." https://pmc.ncbi.nlm.nih.gov/articles/PMC2875212/

Note that at high enough concentrations in the bloodstream, all of the unsaturated fatty acids mentioned above, including linoleic acid, will actually dampen prostanoid overproduction. Saturated fatty acid molecules are not mentioned. That's because they cannot compete with arachidonic acid molecules for membrane lipid positions normally occupied by AA and the other unsaturated fatty acid molecules. That explains this AI Overview that comes up when I do a 'Calder Linoleic Acid 2024' web search. "Recent research in 2024 suggests that linoleic acid (LA), a primary dietary n-6 polyunsaturated fatty acid, has cardiometabolic benefits rather than the previously feared harmful effects, with higher LA intakes correlating to reduced risks of heart disease, stroke, and type 2 diabetes."

Two articles about linoleic acid were pubiished in quick succession in dfferent journals. Kristina H. Jackson, William S. Harris, Martha A. Belury, & Philip C. Calder were co-authors of both articles.

The September article was entitled Beneficial effects of linoleic acid on cardiometabolic health: an update. https://lipidworld.biomedcentral.com/articles/10.1186/s12944-024-02246-2

The October article was entitled 'Perspective on the health effects of unsaturated fatty acids and commonly consumed plant oils high in unsaturated fat'. https://pmc.ncbi.nlm.nih.gov/articles/PMC11600290/

Both articles are excellent examples of paltering - using the truth to mislead.

For some reason Philip Calder doesn't seem to realize that their conclusions are based on an incomplete data set. Calder was president of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) from 2009 to 2012. Apparently, he forgot this declaration. "All agreed that a 5-year randomized controlled trial comparing the effects of historically low (2%) with currently high (7.5%) linoleic acid intakes on cardiac endpoints would address the knowledge gap about the effects of different omega-6 PUFA intakes on the risk of heart disease." https://karger.com/anm/article/58/1/59/40551/ISSFAL-2010-Dinner-Debate-Healthy-Fats-for-Healthy

It's likely the study would have shown that 2% or less linoleic acid intake would translate into a huge reduction in mortality no matter how much saturated fat subjects consumed.

As far as I can tell, that sort of study was never funded, so the knowledge gap persists.

Expand full comment
10 more comments...

No posts